https://www.selleckchem.com/products/bai1.html
40, 95% CI 0.32-0.50, P = 0.00, better overall survival (HR 0.37, 95% CI 0.19-0.71, P = 0.003), better leukemia-free survival (HR 0.20, 95% CI 0.10-0.40, P = 0.00. However, post-HSCT did not influence OS in Caucasians, and CAR-T cells with CD28 co-stimulation factor bridged to HSCT did not influence OS. Post-HSCT decreased the relapse rate and improved the long-term survival of R/R B-ALL patients. R/R B-ALL patients would benefit from post-HSCT after CAR-T cell therapy. The aim is to offer an overview of the existing training programs